# REFLECTION (Galleri real-world learning programme)

Source: https://onco.cc/trials/reflection-galleri/  
OnCo record `reflection-galleri` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A registry that follows about 14,600 people who paid for or were offered Galleri in ordinary US clinics, to see how the test performs outside a trial.

## Summary

REFLECTION (NCT05205967) is an observational study sponsored by GRAIL, Inc. Its primary outcome is signal detection and cancer detection within and across sites among people who opted to have Galleri.

The registry record, read on 29 October 2026, gives its status as active, not recruiting, with 14,633 participants enrolled, a start on 23 August 2021 and primary completion on 30 September 2025.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-10-29
- Also known as: REFLECTION; GRAIL-MA-001
- Registry id: NCT05205967
- Phase: observational
- Setting: People in the United States who chose to have the Galleri test in routine clinical care, followed for signal and cancer detection
- Sponsor: GRAIL, Inc.
- Enrolled: 14633

## Sources

- ClinicalTrials.gov NCT05205967: https://clinicaltrials.gov/study/NCT05205967

## Connected records

- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- drugs: [Galleri](https://onco.cc/drugs/galleri/)
- companies: [GRAIL](https://onco.cc/companies/grail/)

---
JSON: https://onco.cc/api/v1/entities/reflection-galleri.json